Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225452 | 1.00 | TLR2 (0.49) | TLR2SIRT2SIRT1SIRT3PTPN1 | |
| SCHEMBL15674187 | 0.97 | PTPN1 (0.49) | TLR2SIRT2SIRT1SIRT3PTPN1 | |
| SCHEMBL23253718 | 0.94 | PTPN1 (0.50) | PTPN1 | |
| SCHEMBL12972289 | 0.92 | PTPN1 (0.47) | SIRT2SIRT1SIRT3PTPN1 | |
| SCHEMBL2734926 | 0.92 | PTPN1 (0.47) | SIRT2SIRT1SIRT3PTPN1 | |
| SCHEMBL14374823 | 0.89 | MMP2 (0.54) | TLR2 | |
| SCHEMBL16450347 | 0.88 | PTPN1 (0.48) | PTPN1 | |
| SCHEMBL23286080 | 0.87 | PTPN1 (0.45) | SIRT2SIRT1SIRT3PTPN1 | |
| SCHEMBL30518584 | 0.85 | PTPN1 (0.45) | SIRT2SIRT1PTPN1 | |
| SCHEMBL26015705 | 0.85 | TLR2 (0.46) | TLR2SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090226465-A1 | MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090117100-A1 | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates | GENENTECH, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090068202-A1 | Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090068178-A1 | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin | GENENTECH, INC. (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068178-A1 | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin | HCLS1, CD47, MCL1 | TLR2 2930/4885SIRT2 4045/4885SIRT1 4339/4885 |
| US-20090117100-A1 | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates | PCTP, LNPEP, SLC3A2 | TLR2 533/4885SIRT2 3394/4885SIRT1 4813/4885 |
| US-20090068202-A1 | Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | TLR2 3128/4885SIRT2 4692/4885SIRT1 4864/4885 |
| US-20090226465-A1 | MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS | APLNR, APMAP, CD22 | TLR2 637/4885SIRT2 1367/4885SIRT1 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.